Table 3.

Number of patients with dose reductions at the second cycle and compliance with guidelines

Standard met and dose reduction in the second cycle
	Dose reduction		Standard dose
	n	%	n	%
Lung cancer
Yes (with G-CSF)	42	22.5	116	30.1
Yes (without risk factors)	6	3.2	23	6.0
Yes (dose reduction without G-CSF)	58	31.0	0	0.0
Yes (dose reduction, no risk factors, no G-CSF)	13	7.0	0	0.0
No (overuse: G-CSF without risk factors)	0	0.0	9	2.3
No (overuse: G-SCF and dose reduction)	11	5.9	0	0.0
No (underuse: dose reduction and risk factors)	14	7.5	0	0.0
No (underuse: no G-CSF)	43	23.0	238	61.7
Gesamt	187	100.0	386	100.0
Breast cancer
Yes (with G-CSF)	10	34.5	428	55.4
Yes (without risk factors)	0	0.0	97	12.6
Yes (dose reduction without G-CSF)	4	13.8	0	0.0
Yes (dose reduction, no risk factors, no G-CSF)	0	0.0	0	0.0
No (overuse: G-CSF without risk factors)	0	0.0	36	4.7
No (overuse: G-SCF and dose reduction)	6	20.7	0	0.0
No (underuse: dose reduction and risk factors)	6	20.7	0	0.0
No (underuse: no G-CSF)	3	10.3	211	27.3
Total	29	100.0	772	100.0